Measuring antiplatelet drug effects in the laboratory

Thrombosis Research

Volumn 120, Issue 3, 2007, Pages 323-336

  Harrison, Paul ^a   Frelinger III, A L ^b   Furman, Mark I ^b   Michelson, Alan D ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; TIROFIBAN; UNCLASSIFIED DRUG; VERIFYNOW;

ACUTE CORONARY SYNDROME; BLOOD CLOTTING PARAMETERS; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; DRUG EFFECT; DRUG MONITORING; HUMAN; LABORATORY; LABORATORY TEST; PREDICTION; PRIORITY JOURNAL; RESEARCH; REVIEW;

ASPIRIN; BLOOD PLATELETS; DRUG RESISTANCE; HUMANS; LABORATORIES; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TICLOPIDINE;

EID: 34249939815     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.11.012     Document Type: Review

References (134)

1. Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 41 (1988) 1322-1330
2. Gawaz M., Langer H., and May A.E. Platelets in inflammation and atherogenesis. J Clin Invest 115 (2005) 3378-3384
3. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
4. Harrison P. Platelet function analysis. Blood Rev 19 (2005) 111-123
5. Harrison P. Progress in the assessment of platelet function. Br J Haematol 111 (2000) 733-744
6. de Guetano G. A new blood corpuscle: an impossible interview with Giulio Bizzozero. Thromb Haemost 86 (2001) 973-979
7. Duke W.W. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and the coagulation time and report of three cases of hemorrhagic disease relieved by blood transfusion. JAMA 55 (1910) 1185-1192
8. Harker L.A., and Slichter S.J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 287 (1972) 155-159
9. Nilsson I.M., Magnusson S., and Borchgrevink C. The Duke and Ivy Methods for determination of the bleeding time. Thromb Diath Haemorrh 10 (1963) 223-234
10. Rodgers R.P., and Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 16 (1990) 1-20
11. Lind S.E. The bleeding time does not predict surgical bleeding. Blood 77 (1991) 2547-2552
12. Peterson P., Hayes T.E., Arkin C.F., Bovill E.G., Fairweather R.B., Rock Jr. W.A., et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 133 (1998) 134-139
13. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194 (1962) 927-929
14. O'Brien J.M. Platelet aggregation. II. Some results from a new method of study. J Clin Pathol 15 (1962) 452-481
15. Zhou L., and Schmaier A.H. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol 123 (2005) 172-183
16. Moffat K.A., Ledford-Kraemer M.R., Nichols W.L., and Hayward C.P. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost 93 (2005) 549-553
17. Cardinal D.C., and Flower R.J. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 3 (1980) 135-158
18. Smith J.W., Steinhubl S.R., Lincoff A.M., Coleman J.C., Lee T.T., Hillman R.S., et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 99 (1999) 620-625
19. Kereiakes D.J., Mueller M., Howard W., Lacock P., Anderson L.C., Broderick T.M., et al. Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombolysis 7 (1999) 265-276
20. Coller B.S., Lang D., and Scudder L.E. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 95 (1997) 860-867
21. Fox S.C., Burgess-Wilson M., Heptinstall S., and Mitchell J.R. Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost 48 (1982) 327-329
22. Heptinstall S., Fox S., Crawford J., and Hawkins M. Inhibition of platelet aggregation in whole blood by dipyridamole and aspirin. Thromb Res 42 (1986) 215-223
23. Glenn J.R., White A.E., Johnson A., Fox S.C., Behan M.W., Dolan G., et al. Leukocyte count and leukocyte ecto-nucleotidase are major determinants of the effects of adenosine triphosphate and adenosine diphosphate on platelet aggregation in human blood. Platelets 16 (2005) 159-170
24. Carville D.G., Schleckser P.A., Guyer K.E., Corsello M., and Walsh M.M. Whole blood platelet function assay on the ICHOR point-of-care hematology analyzer. J Extra Corpor Technol 30 (1998) 171-177
25. Craft R.M., Chavez J.J., Snider C.C., Muenchen R.A., and Carroll R.C. Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J Lab Clin Med 145 (2005) 309-315
26. White M.M., Krishnan R., Kueter T.J., Jacoski M.V., and Jennings L.K. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIb-IIIa antagonists. J Thromb Thrombolysis 18 (2004) 163-169
27. Lennon M.J., Gibbs N.M., Weightman W.M., McGuire D., and Michalopoulos N. A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 18 (2004) 136-140
28. Spectre G., Brill A., Gural A., Shenkman B., Touretsky N., Mosseri E., et al. A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer. Platelets 16 (2005) 293-299
29. Kenet G., Lubetsky A., Shenkman B., Tamarin I., Dardik R., Rechavi G., et al. Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 101 (1998) 255-259
30. Varon D., Lashevski I., Brenner B., Beyar R., Lanir N., Tamarin I., et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 135 (1998) S187-S193
31. Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol 130 (2005) 3-10
32. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 138 (2001) 152-163
33. Kundu S.K., Heilmann E.J., Sio R., Garcia C., and Ostgaard R.A. Characterization of an in vitro platelet function analyzer - PFA-100. Clin Appl Thromb Hemost 2 (1996) 241-249
34. Kundu S.K., Heilmann E.J., Sio R., Garcia C., Davidson R.M., and Ostgaard R.A. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 21 Suppl 2 (1995) 106-112
35. Caen J.P., and Rosa J.P. Platelet-vessel wall interaction: from the bedside to molecules. Thromb Haemost 74 (1995) 18-24
36. Gerotziafas G.T., Depasse F., Busson J., Leflem L., Elalamy I., and Samama M.M. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay. Thromb J 3 (2005) 16
37. Al D.R., Peyvandi F., Santagostino E., Giansily M., Mannucci P.M., Schved J.F., et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 88 (2002) 576-582
38. Hemker H.C., and Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 74 (1995) 134-138
39. Coiffic A., Cazes E., Janvier G., Forestier F., Lanza F., Nurden A., et al. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus. Thromb Res 95 (1999) 83-91
40. Despotis G.J., Levine V., Saleem R., Spitznagel E., and Joist J.H. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: a randomised controlled trial. Lancet 354 (1999) 106-110
41. Despotis G.J., Levine V., Filos K.S., Santoro S.A., Joist J.H., Spitznagel E., et al. Evaluation of a new point-of-care test that measures PAF-mediated acceleration of coagulation in cardiac surgical patients. Anesthesiology 85 (1996) 1311-1323
42. Luddington R.J. Thromboelastography/thromboelastometry. Clin Lab Haematol 27 (2005) 81-90
43. Salooja N., and Perry D.J. Thromboelastography. Blood Coagul Fibrinolysis 12 (2001) 327-337
44. Hartert H. Thrombelastography, a method for physical analysis of blood coagulation. Z Gesamte Exp Med 117 (1951) 189-203
45. Lang T., Bauters A., Braun S.L., Potzsch B., von Pape K.W., Kolde H.J., et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis 16 (2005) 301-310
46. Tantry U.S., Bliden K.P., and Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 46 (2005) 1705-1709
47. Bowbrick V.A., Mikhailidis D.P., and Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost 9 (2003) 137-142
48. Carr Jr. M.E., and Zekert S.L. Measurement of platelet-mediated force development during plasma clot formation. Am J Med Sci 302 (1991) 13-18
49. Carr M.E., Martin E.J., Kuhn J.G., and Spiess B.D. Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). J Thromb Haemost 1 (2003) 1977-1983
50. Carr Jr. M.E. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 38 (2003) 55-78
51. Carr Jr ME. Measurement of platelet force: the Hemodyne hemostasis analyzer. Clin.Lab Manage.Rev. 1995;9:312-8, 320.
52. Michelson A.D., and Furman M.I. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol 6 (1999) 342-348
53. Schmitz G., Rothe G., Ruf A., Barlage S., Tschope D., Clemetson K.J., et al. European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 79 (1998) 885-896
54. Michelson A.D. Flow cytometry: a clinical test of platelet function. Blood 87 (1996) 4925-4936
55. Michelson A.D. Platelet function testing in cardiovascular diseases. Circulation 110 (2004) e489-e493
56. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24 (2004) 1980-1987
57. Michelson A.D., Cattaneo M., Eikelboom J.W., Gurbel P., Kottke-Marchant K., Kunicki T.J., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3 (2005) 1309-1311
58. Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
59. Szczeklik A., Musial J., Undas A., and Sanak M. Aspirin resistance. J Thromb Haemost 3 (2005) 1655-1662
60. Roth G.J., and Majerus P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 56 (1975) 624-632
61. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
62. Rocca B., and Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 3 (2005) 1597-1602
63. Schwartz K.A., Schwartz D.E., Ghosheh K., Reeves M.J., Barber K., and DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95 (2005) 973-975
64. Frelinger III A.L., Furman M.I., Linden M.D., Li Y., Fox M.L., Barnard M.R., et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway. A 700-patient study of aspirin resistance. Circulation 113 (2006) 2888-2896
65. Weber A.A., Przytulski B., Schanz A., Hohlfeld T., and Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 13 (2002) 37-40
66. Homoncik M., Jilma B., Hergovich N., Stohlawetz P., Panzer S., and Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 83 (2000) 316-321
67. Feuring M., Schultz A., Losel R., and Wehling M. Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. Semin Thromb Hemost 31 (2005) 411-415
68. Andersen K., Hurlen M., Arnesen H., and Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108 (2002) 37-42
69. Sambola A., Heras M., Escolar G., Lozano M., Pino M., Martorell T., et al. The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin. Platelets 15 (2004) 439-446
70. Coakley M., Self R., Marchant W., Mackie I., Mallett S.V., and Mythen M. Use of the platelet function analyser (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease. Anaesthesia 60 (2005) 1173-1178
71. Coma-Canella I., Velasco A., and Castano S. Prevalence of aspirin resistance measured by PFA-100. Int J Cardiol 101 (2005) 71-76
72. Peters A.J., Borries M., Gradaus F., Jax T.W., Schoebel F.C., and Strauer B.E. In vitro bleeding test with PFA-100-aspects of controlling individual acetylsalicylic acid induced platelet inhibition in patients with cardiovascular disease. J Thromb Thrombolysis 12 (2001) 263-272
73. Harrison P., Mackie I., Mathur A., Robinson M.S., Hong Y., Erusalimsky J.D., et al. Platelet hyper-function in acute coronary syndromes. Blood Coagul Fibrinolysis 16 (2005) 557-562
74. McCabe D.J., Harrison P., Mackie I.J., Sidhu P.S., Lawrie A.S., Purdy G., et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 16 (2005) 269-280
75. Alberts M.J., Bergman D.L., Molner E., Jovanovic B.D., Ushiwata I., and Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
76. Chakroun T., Gerotziafas G., Robert F., Lecrubier C., Samama M.M., Hatmi M., et al. In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol 124 (2004) 80-85
77. Frossard M., Fuchs I., Leitner J.M., Hsieh K., Vlcek M., Losert H., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110 (2004) 1392-1397
78. Macchi L., Christiaens L., Brabant S., Sorel N., Allal J., Mauco G., et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107 (2002) 45-49
79. Harrison P., Segal H., Blasbery K., Furtado C., Silver L., and Rothwell P.M. Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry. Stroke 36 (2005) 1001-1005
80. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
81. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
82. Steinhubl S.R., Varanasi J.S., and Goldberg L. Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 42 (2003) 1336-1337
83. Jilma B. Therapeutic failure or resistance to aspirin. J Am Coll Cardiol 43 (2004) 1332-1333
84. Eikelboom J.W., and Hankey G.J. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol 41 (2003) 966-968
85. Grundmann K., Jaschonek K., Kleine B., Dichgans J., and Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250 (2003) 63-66
86. Lanza G.A., Sestito A., Iacovella S., Morlacchi L., Romagnoli E., Schiavoni G., et al. Relation between platelet response to exercise and coronary angiographic findings in patients with effort angina. Circulation 107 (2003) 1378-1382
87. Fuchs I., Frossard M., Spiel A., Mayr F., Laggner B., and Jilma N. Platelet hyperfunction and low response to aspirin predict re-events in patients with acute coronary syndromes during long term follow up. J Thromb Haemost 3 supplement 1 (2005) [abstract P2142]
88. Christie D.J., Kottke-Marchant K., and Gorman R. High shear platelet function is associated with major adverse events in patients with Stable cardiovascular disease (CVD) despite aspirin therapy. J Thromb Haemost 3 supplement 1 (2005) [abstract P2204]
89. Stejskal D., Proskova J., Petrzelova A., Bartek J., Oral I., Lacnak B., et al. Application of cationic propyl gallate as inducer of thrombocyte aggregation for evaluation of effectiveness ofantiaggregation therapy. Biomed Pap Med Fac Palacky Univ Olomouc Czech Repub 145 (2001) 69-74
90. Malinin A., Spergling M., Muhlestein B., Steinhubl S., and Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 15 (2004) 295-301
91. Wang J.C., ucoin-Barry D., Manuelian D., Monbouquette R., Reisman M., Gray W., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 92 (2003) 1492-1494
92. Chen W.H., Lee P.Y., Ng W., Kwok J.Y., Cheng X., Lee S.W., et al. Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol 96 (2005) 760-763
93. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
94. Lee P.Y., Chen W.H., Ng W., Cheng X., Kwok J.Y., Tse H.F., et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 118 (2005) 723-727
95. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
96. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 46 (2005) 277-300
97. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
98. Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
99. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
100. Savi P., and Herbert J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31 (2005) 174-183
101. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., and Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45 (2005) 246-251
102. Nguyen T.A., Diodati J.G., and Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45 (2005) 1157-1164
103. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
104. Jaremo P., Lindahl T.L., Fransson S.G., and Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 252 (2002) 233-238
105. Lau W.C., Gurbel P.A., Watkins P.B., Neer C.J., Hopp A.S., Carville D.G., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
106. Michelson A.D., Linden M.D., Furman M.I., Mi L.F., Barnard M.R., Fox M.L., et al. Pre-existent variability in platelet response to ADP accounts for clopidogrel resistance. J Thromb Haemost 3 supplement 1 (2005) [Abstract P0955]
107. Geiger J., Teichmann L., Grossmann R., Aktas B., Steigerwald U., Walter U., et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 51 (2005) 957-965
108. Mobley J.E., Bresee S.J., Wortham D.C., Craft R.M., Snider C.C., and Carroll R.C. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. Am J Cardiol 93 (2004) 456-458
109. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., and Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45 (2005) 1392-1396
110. Muller I., Seyfarth M., Rudiger S., Wolf B., Pogatsa-Murray G., Schomig A., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85 (2001) 92-93
111. Gurbel P.A., Bliden K.P., Zaman K.A., Yoho J.A., Hayes K.M., and Tantry U.S. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 111 (2005) 1153-1159
112. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A., and Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3 (2005) 85-92
113. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
114. Fox S.C., Behan M.W., and Heptinstall S. Inhibition of ADP-induced intracellular Ca2+responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandin E1. Cell Calcium 35 (2004) 39-46
115. Gachet C., Cazenave J.P., Ohlmann P., Bouloux C., Defreyn G., Driot F., et al. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem Pharmacol 40 (1990) 2683-2687
116. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59 (2003) 295-302
117. Golanski J., Pluta J., Baraniak J., and Watala C. Limited usefulness of the PFA-100 for the monitoring of ADP receptor antagonists - in vitro experience. Clin Chem Lab Med 42 (2004) 25-29
118. Mueller T., Haltmayer M., Poelz W., and Haidinger D. Monitoring aspirin 100 mg and clopidogrel 75 mg therapy with the PFA-100 device in patients with peripheral arterial disease. Vasc Endovascular Surg 37 (2003) 117-123
119. Ziegler S., Maca T., Alt E., Speiser W., Schneider B., and Minar E. Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13 (2002) 493-497
120. Pidcock M., and Harrison P. Can the PFA-100 be modified to detect P2Y12 inhibition?. J Thromb Haemost 4 (2006) 1424-1426
121. Raman S., and Jilma B. Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA-100. J Thromb Haemost 2 (2004) 2278-2279
122. Jilma B. Synergistic antiplatelet effects of Clopidogrel and aspirin detected with the PFA-100 in stroke patients. Stroke 34 4 (2003) 849-854
123. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46 (2005) 1827-1832
124. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
125. Coller B.S., Folts J.D., Smith S.R., Scudder L.E., and Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation 80 (1989) 1766-1774
126. Gold H.K., Coller B.S., Yasuda T., Saito T., Fallon J.T., Guerrero J.L., et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 77 (1988) 670-677
127. Thompson C.M., and Steinhubl S.R. Monitoring of platelet function in the setting of GPIIa/IIIb inhibitor therapy. Curr Interv Cardiol Rep 1 (1999) 270-277
128. Wheeler G.L., Braden G.A., Steinhubl S.R., Kereiakes D.J., Kottke-Marchant K., Michelson A.D., et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 143 (2002) 602-611
129. Simon D.I., Liu C.B., Ganz P., Kirshenbaum J.M., Piana R.N., Rogers C., et al. A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheter Cardiovasc Interv 52 (2001) 425-432
130. Steinhubl S.R., Talley J.D., Braden G.A., Tcheng J.E., Casterella P.J., Moliterno D.J., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU - Assessing Ultegra) multicenter study. Circulation 103 (2001) 2572-2578
131. Hezard N., Metz D., Nazeyrollas P., Droulle C., Elaerts J., Potron G., et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb Haemost 83 (2000) 540-544
132. Madan M., Berkowitz S.D., Christie D.J., Jennings L.K., Smit A.C., Sigmon K.N., et al. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J 141 (2001) 226-233
133. Madan M., Berkowitz S.D., Christie D.J., Smit A.C., Sigmon K.N., and Tcheng J.E. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 144 (2002) 151-158
134. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., Jacobs A.K., Kern M.J., King III S.B., et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) 156-175